Biotech-Focused Hedge Funds Back Talawar’s Fast Moving SPAC Merger

RA Capital, Deep Track and other healthcare investors joined a $225 million PIPE supporting Talawar Therapeutics’ deal with JATT II, which found a merger partner just over two months after its IPO.

Stephen Taub July 2, 2026

Several prominent biotech-focused hedge funds are backing Talawar Therapeutics' merger with JATT II Acquisition, a special purpose acquisition company that found a merger partner just over two months after going public.Talawar Therapeutics, a biotech company developing bispecific antibodies that pair independent immunology and inflammatory disease

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2026 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.24.00 build:2026-06-22 Login